/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
/f/125658/3386x1417/951de003e4/hfa-acronym-name-rgb.png)
Brian Halliday is an Academic Clinical Lecturer at the National Heart and Lung Institute, based at the Cardiovascular Research Centre at the Royal Brompton Campus. He completed his undergraduate training at University of Edinburgh, before moving to London to continue his clinical training. In 2015, he started a PhD at the NHLI. This included the TRED-HF trial, which set out to examine the safety and feasibility of therapy withdrawal in patients deemed to have recovered dilated cardiomyopathy. He presented the results at the Late Breaking Clinical Trial Sessions at the American Heart Association, 2018 and was primary author of the simultaneous publication in The Lancet. He also investigated the use of CMR for the risk stratification of patients with dilated cardiomyopathy, focusing on improving the selection of patients for implantable cardioverter defibrillators. He has published articles in several high-impact journals on this topic.
